Business Context and Reporting Period
Company: Pharming Group N.V.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Date: May 28, 2026
Context: This filing reports on the results of the Annual General Meeting of Shareholders (AGM) held on May 28, 2026, and discloses a change in the Company's external auditor.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the period. The document focuses exclusively on corporate governance and auditor changes.
Material Changes
- Auditor Change: The AGM approved the appointment of KPMG Accountants N.V. as the external auditor for the financial years 2026, 2027, and 2028, replacing Deloitte Accountants B.V.
- Termination of Prior Auditor: Deloitte was dismissed as external auditor on May 28, 2026.
- Shareholder Approvals: Shareholders approved amendments to the Remuneration policy for Non-Executive Directors, as well as authorizations for the Board to issue and repurchase shares.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms that all proposals presented at the AGM were approved by shareholders. No specific financial guidance or operational outlook was provided in this document.
Risks and Contingencies:
- Audit Disagreements: The Company reported no disagreements with Deloitte regarding accounting principles, practices, or audit scope during the fiscal years ended December 31, 2025 and 2024, or the subsequent period through May 28, 2026.
- Internal Controls: The filing notes that the only reportable event during the relevant period was the material weaknesses in internal control over financial reporting previously disclosed in the Company's Annual Report on Form 20-F for the year ended December 31, 2024.
- Auditor Opinion: Deloitte's reports for the years ended December 31, 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications.
Investor Verification Checklist
- Verify the specific terms of the new audit engagement with KPMG for the 2026-2028 period.
- Review the details of the material weaknesses in internal control over financial reporting disclosed in the 2024 Form 20-F to assess remediation progress.
- Confirm the details of the amended Remuneration policy for Non-Executive Directors.
- Check the Company's website for the AGM webcast recording and detailed voting results.